Immunovant IncNASDAQ:IMVT
- LAST PRICE28.9000
- TODAY'S CHANGE (%)-0.1800 (-0.6190%)
- Bid / Lots28.4000/ 3
- Ask / Lots31.0000/ 1
- Open / Previous Close29.5700 / 29.0800
- Day Range
- 52 Week Range
- Volume785,586
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMVT |
|---|---|---|
| 09:32 ET | 7122 | 29.61 |
| 09:34 ET | 2200 | 29.61 |
| 09:36 ET | 1000 | 29.35 |
| 09:38 ET | 16610 | 29.54 |
| 09:39 ET | 900 | 29.38 |
| 09:41 ET | 400 | 29.51 |
| 09:43 ET | 1200 | 29.625 |
| 09:45 ET | 2927 | 29.615 |
| 09:48 ET | 1200 | 29.55 |
| 09:50 ET | 400 | 29.48 |
| 09:52 ET | 2094 | 29.47 |
| 09:54 ET | 400 | 29.425 |
| 09:56 ET | 400 | 29.495 |
| 09:57 ET | 700 | 29.49 |
| 09:59 ET | 1147 | 29.42 |
| 10:01 ET | 700 | 29.41 |
| 10:03 ET | 400 | 29.4275 |
| 10:06 ET | 910 | 29.37 |
| 10:08 ET | 1200 | 29.31 |
| 10:10 ET | 300 | 29.3 |
| 10:12 ET | 1000 | 29.3 |
| 10:14 ET | 900 | 29.34 |
| 10:15 ET | 768 | 29.22 |
| 10:17 ET | 3899 | 29.27 |
| 10:19 ET | 200 | 29.2 |
| 10:21 ET | 5646 | 29.19 |
| 10:24 ET | 2273 | 29.315 |
| 10:26 ET | 1500 | 29.28 |
| 10:28 ET | 100 | 29.25 |
| 10:30 ET | 600 | 29.305 |
| 10:32 ET | 500 | 29.265 |
| 10:33 ET | 3764 | 29.305 |
| 10:37 ET | 900 | 29.405 |
| 10:39 ET | 400 | 29.41 |
| 10:42 ET | 582 | 29.39 |
| 10:46 ET | 600 | 29.36 |
| 10:50 ET | 500 | 29.395 |
| 10:51 ET | 873 | 29.415 |
| 10:55 ET | 1430 | 29.42 |
| 10:57 ET | 1067 | 29.39 |
| 11:00 ET | 300 | 29.4 |
| 11:02 ET | 2300 | 29.5 |
| 11:04 ET | 1406 | 29.4 |
| 11:06 ET | 1200 | 29.34 |
| 11:08 ET | 2200 | 29.25 |
| 11:09 ET | 400 | 29.22 |
| 11:11 ET | 800 | 29.19 |
| 11:13 ET | 400 | 29.14 |
| 11:15 ET | 100 | 29.14 |
| 11:18 ET | 100 | 29.08 |
| 11:20 ET | 200 | 29.105 |
| 11:22 ET | 10328 | 29.045 |
| 11:24 ET | 500 | 29.02 |
| 11:26 ET | 200 | 29.01 |
| 11:27 ET | 560 | 28.98 |
| 11:29 ET | 600 | 28.98 |
| 11:31 ET | 600 | 28.94 |
| 11:33 ET | 2307 | 28.845 |
| 11:36 ET | 400 | 28.81 |
| 11:38 ET | 6675 | 28.815 |
| 11:40 ET | 1450 | 28.84 |
| 11:42 ET | 300 | 28.83 |
| 11:44 ET | 1359 | 28.79 |
| 11:45 ET | 3848 | 28.93 |
| 11:47 ET | 900 | 28.87 |
| 11:49 ET | 1247 | 28.845 |
| 11:51 ET | 860 | 28.82 |
| 11:54 ET | 319 | 28.82 |
| 11:56 ET | 500 | 28.815 |
| 11:58 ET | 500 | 28.77 |
| 12:00 ET | 2330 | 28.73 |
| 12:02 ET | 400 | 28.7 |
| 12:05 ET | 600 | 28.65 |
| 12:07 ET | 1925 | 28.71 |
| 12:09 ET | 300 | 28.71 |
| 12:12 ET | 2900 | 28.73 |
| 12:14 ET | 400 | 28.725 |
| 12:16 ET | 600 | 28.72 |
| 12:18 ET | 11989 | 28.695 |
| 12:20 ET | 2327 | 28.735 |
| 12:21 ET | 100 | 28.73 |
| 12:23 ET | 1800 | 28.64 |
| 12:25 ET | 1008 | 28.63 |
| 12:27 ET | 2305 | 28.655 |
| 12:30 ET | 334 | 28.66 |
| 12:32 ET | 400 | 28.65 |
| 12:34 ET | 1932 | 28.59 |
| 12:36 ET | 2986 | 28.56 |
| 12:38 ET | 4925 | 28.585 |
| 12:39 ET | 9287 | 28.6195 |
| 12:41 ET | 100 | 28.63 |
| 12:43 ET | 500 | 28.58 |
| 12:45 ET | 800 | 28.54 |
| 12:48 ET | 990 | 28.51 |
| 12:50 ET | 1540 | 28.49 |
| 12:52 ET | 420 | 28.5 |
| 12:54 ET | 2508 | 28.5 |
| 12:56 ET | 497 | 28.51 |
| 12:57 ET | 1307 | 28.6 |
| 12:59 ET | 833 | 28.58 |
| 01:01 ET | 1948 | 28.57 |
| 01:03 ET | 1720 | 28.585 |
| 01:06 ET | 940 | 28.55 |
| 01:08 ET | 1360 | 28.53 |
| 01:10 ET | 1340 | 28.525 |
| 01:12 ET | 724 | 28.51 |
| 01:14 ET | 500 | 28.525 |
| 01:15 ET | 4539 | 28.595 |
| 01:17 ET | 400 | 28.605 |
| 01:19 ET | 1000 | 28.61 |
| 01:21 ET | 1101 | 28.635 |
| 01:24 ET | 1200 | 28.61 |
| 01:26 ET | 1881 | 28.69 |
| 01:28 ET | 1350 | 28.68 |
| 01:30 ET | 2000 | 28.695 |
| 01:32 ET | 500 | 28.765 |
| 01:33 ET | 4710 | 28.84 |
| 01:35 ET | 2400 | 28.8 |
| 01:37 ET | 820 | 28.865 |
| 01:39 ET | 1480 | 28.865 |
| 01:42 ET | 2600 | 28.835 |
| 01:44 ET | 500 | 28.74 |
| 01:46 ET | 1032 | 28.64 |
| 01:48 ET | 1439 | 28.665 |
| 01:50 ET | 600 | 28.64 |
| 01:51 ET | 1869 | 28.72 |
| 01:53 ET | 2013 | 28.72 |
| 01:55 ET | 200 | 28.7 |
| 01:57 ET | 1190 | 28.67 |
| 02:00 ET | 1100 | 28.77 |
| 02:02 ET | 5200 | 29.35 |
| 02:04 ET | 6028 | 29.34 |
| 02:06 ET | 1002 | 29.06 |
| 02:08 ET | 2574 | 29.11 |
| 02:09 ET | 500 | 29.01 |
| 02:11 ET | 3148 | 29.13 |
| 02:13 ET | 7458 | 29.01 |
| 02:15 ET | 2500 | 29.1 |
| 02:18 ET | 1220 | 29.315 |
| 02:20 ET | 1244 | 29.33 |
| 02:22 ET | 1129 | 29.44 |
| 02:24 ET | 2260 | 29.33 |
| 02:26 ET | 1283 | 29.41 |
| 02:27 ET | 1400 | 29.33 |
| 02:29 ET | 23645 | 29.39 |
| 02:31 ET | 2899 | 29.37 |
| 02:33 ET | 5878 | 29.44 |
| 02:36 ET | 16411 | 29.505 |
| 02:38 ET | 4426 | 29.43 |
| 02:40 ET | 9000 | 29.44 |
| 02:42 ET | 3160 | 29.43 |
| 02:44 ET | 5915 | 29.32 |
| 02:45 ET | 4825 | 29.12 |
| 02:47 ET | 1700 | 29.405 |
| 02:49 ET | 2501 | 29.36 |
| 02:51 ET | 1332 | 29.44 |
| 02:54 ET | 3219 | 29.53 |
| 02:56 ET | 500 | 29.5 |
| 02:58 ET | 3320 | 29.45 |
| 03:00 ET | 3440 | 29.38 |
| 03:02 ET | 1344 | 29.2 |
| 03:03 ET | 2017 | 29.21 |
| 03:05 ET | 590 | 29.42 |
| 03:07 ET | 1873 | 29.265 |
| 03:09 ET | 1403 | 29.295 |
| 03:12 ET | 1313 | 29.31 |
| 03:14 ET | 2348 | 29.5 |
| 03:16 ET | 100 | 29.465 |
| 03:18 ET | 500 | 29.35 |
| 03:20 ET | 982 | 29.405 |
| 03:21 ET | 100 | 29.41 |
| 03:23 ET | 1116 | 29.22 |
| 03:25 ET | 1184 | 29.28 |
| 03:27 ET | 900 | 29.42 |
| 03:30 ET | 2434 | 29.465 |
| 03:32 ET | 500 | 29.38 |
| 03:34 ET | 1539 | 29.325 |
| 03:36 ET | 500 | 29.18 |
| 03:38 ET | 894 | 29.08 |
| 03:39 ET | 1400 | 29.095 |
| 03:41 ET | 800 | 29.1 |
| 03:43 ET | 800 | 29.12 |
| 03:45 ET | 2989 | 29.06 |
| 03:48 ET | 300 | 29 |
| 03:50 ET | 1272 | 28.97 |
| 03:52 ET | 4831 | 29.03 |
| 03:54 ET | 2832 | 28.99 |
| 03:56 ET | 4900 | 28.94 |
| 03:57 ET | 6520 | 28.86 |
| 03:59 ET | 138616 | 28.9 |
Sep 10, 2024
DJ Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co., from 7:25AM ET on Tuesday Sep 10, 2024 by Dow Jones
7:25AM ET on Tuesday Sep 10, 2024 by Dow Jones
Sep 9, 2024
Roivant Provides Update on Graves' Disease Development Program, from 7:00AM ET on Monday Sep 09, 2024 by Dow Jones
7:00AM ET on Monday Sep 09, 2024 by Dow JonesImmunovant Provides Update on Graves' Disease Development Program, from 3:55AM ET on Monday Sep 09, 2024 by Dow Jones
3:55AM ET on Monday Sep 09, 2024 by Dow Jones
Sep 5, 2024
Immunovant to Host Graves' Disease Program Update on September 9, 2024, from 6:30AM ET on Thursday Sep 05, 2024 by Dow Jones
6:30AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Immunovant Inc | 4.3B | -15.1x | --- |
Crinetics Pharmaceuticals Inc | 4.2B | -14.0x | --- |
Biohaven Ltd | 3.7B | -4.3x | --- |
Avidity Biosciences Inc | 4.9B | -15.1x | --- |
Dyne Therapeutics Inc | 3.5B | -9.6x | --- |
Madrigal Pharmaceuticals Inc | 5.1B | -9.1x | --- |
Company Information
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Contact Information
- Headquarters
- 320 West 37Th StreetNEW YORK, NY, United States 10018
- Phone
- 917-580-3099
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board
- Frank Torti
- Chief Executive Office, Director
- Peter Salzmann
- Chief Financial Officer
- Eva Barnett
- Chief Technology Officer
- Jay Stout
- Chief Development Officer
- Julia Butchko
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.3B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 146.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.72 |
EPS | $-1.92 |
Book Value | $4.24 |
P/E Ratio | -15.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
